Lentigo Maligna
12
0
1
8
Key Insights
Highlights
Success Rate
89% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
8.3%
1 terminated out of 12 trials
88.9%
+2.4% vs benchmark
25%
3 trials in Phase 3/4
13%
1 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (12)
Prospective Study of Ingenol Mebutate for Non-invasive Lentigo Melanoma of the Face
Complications and Recurrences After Mohs Micrographic Surgery and Slow Mohs
Comparison of 3 in Vivo Microscopic Imaging Techniques for the Diagnosis of Pigmented Tumors
Radiotherapy or Imiquimod in Complex Lentigo Maligna
Use of Electrical Impedance Spectroscopy (EIS) for Early Diagnosis of Skin Damage
Reflectance Confocal Microscopy to Diagnose MM & LM
Imiquimod to Detect Residual Lesions and Prevent Recurrence of Lentigo Maligna
Mohs and Immunofluorescence for Malignant Melanoma In Situ
Photodynamic Therapy for Lentigo Maligna Using 5-aminolevulinic Acid Nanoemulsion as a Light Sensitizing Cream
Combination Therapy With Imiquimod Cream 5% and Tazarotene Cream 0.1% for the Treatment of Lentigo Maligna
In Vivo Confocal Microscopy for Pigmented Lesion Diagnosis
Effect of Topical Imiquimod on Lentigo Maligna